ABT
$109.95
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Recent News
Abbott Diabetes And Cardiology Updates Test Growth Story For Investors
Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system for people with Type 2 diabetes using basal insulin. The company also introduced its next generation XIENCE Skypoint drug eluting stent in India, expanding its interventional cardiology offering. These developments highlight fresh clinical data in diabetes care and a broader global rollout of Abbott’s cardiovascular technologies. At a share price of $109.95, Abbott...
This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?
This Dividend King is suddenly on sale. Should you buy the dip?
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
Abbott (ABT) closed at $109.95 in the latest trading session, marking a +1.78% move from the prior day.
GEHC vs. ABT: Which Stock Is the Better Value Option?
GEHC vs. ABT: Which Stock Is the Better Value Option?
Abbott Laboratories (ABT) Unveils XIENCE Skypoint to Advance Cardiovascular Treatment in India
Abbott Laboratories (NYSE:ABT) is one of Goldman Sachs top healthcare stocks. On March 10, Abbott Laboratories (NYSE:ABT) confirmed the launch of its most advanced generation stent, XIENCE Skypoint, in India. The launch is designed to equip doctors in the country with stents that can reach difficult areas and treat a wide range of blockages. XIENCE […]